(Translated by https://www.hiragana.jp/)
Deutsches Krebsforschungszentrum

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential enable/disable

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name	Webedition CMS
Purpose	This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name	econda
Purpose	Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

Statistics enable/disable

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name	econda
Purpose	Statistics

External media enable/disable

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name	YouTube
Purpose	Show YouTube content
Name	Twitter
Purpose	activate Twitter Feeds

Research

Clinical Cooperation Unit Dermato-Oncology

Prof. Dr. Jochen Sven Utikal

Primary malignant melanoma
© dkfz.de

The Clinical Cooperation Unit Dermato-Oncology is engaged in the diagnosis and therapy of skin tumors. Research results obtained are transferred directly into clinical practice. The main focus is on malignant melanoma, a tumor that originates from the pigment cells of the skin. The Clinical Cooperation Unit Dermato-Oncology conducts several translational research projects, including different Phase I-IV clinical trials, with innovative melanoma therapies. (LINK: clinical trials)

Translational research focuses on cellular plasticity of melanoma cells, target identification to overcome resistance mechanisms, immunosuppression in melanoma, and prognostic and predictive melanoma biomarker.

Contact

Prof. Dr. Jochen Sven Utikal

Dermato-Oncology (A370)

Deutsches Krebsforschungszentrum

Im Neuenheimer Feld 280

69120 Heidelberg

Tel: +49 621 383 4461

E-Mail: j.utikal@dkfz-heidelberg.de

Selected Publications

Sahin U et al., (2020). An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature, 585(7823):107-112.
Bitsch R, et al. (2022). STAT3 inhibitor Napabucasin abrogates MDSC immunosuppressive capacity and prolongs survival of melanoma-bearing mice. J Immunother Cancer; 10(3):e004384.
Arkhypov I et al. (2022). HSP90? induces immunosuppressive myeloid cells in melanoma via TLR4 signaling. J Immunother Cancer, 10(9):e005551.
Steinfass T, et al. (2023). Secretogranin II influences the assembly and function of MHC class I in melanoma. Exp Hematol Oncol. 12:29.